title: Anti-cell proliferative and anti-angiogenic potential of andrographolide during 7,12- dimethylbenz(a)anthracene induced hamster buccal pouch carcinogenesis.
abstract: Our aim was to explore anti-cell proliferative and anti-angiogenic potential of andrographolide by analyzing the expression pattern of cell proliferative (PCNA, Cyclin D1) and angiogenic (VEGF) markers during 7, 12-dimethylbenz(a)anthracene (DMBA) induced hamster buccal pouch carcinogenesis. DMBA painting three times a week for 14 weeks in the buccal pouch of golden Syrian hamsters resulted in oral tumors which were histopathologically diagnosed as well differentiated squamous cell carcinoma. Immunohistochemical (PCNA, VEGF) and RT-PCR (Cyclin D1) studies revealed over expression of PCNA, VEGF and Cyclin D1 in the buccal mucosa of hamsters treated with DMBA alone. Oral administration of andrographolide at a dose of 50 mg/kg bw to hamsters treated with DMBA not only suppressed the histological abnormalities but also down regulated the expression of PCNA, VEGF and Cyclin D1. The results of the present study suggest that andrographolide suppressed tumor formation in the buccal mucosa of hamsters treated with DMBA through its anti-cell proliferative and anti-angiogenic potential.
authors.affiliation: Department of Biochemistry and Biotechnology, Annamalai University, Tamilnadu, India E-mail : rasmanshisak@gmail.com.
authors.forename: Arjun Kumar
authors.initials: AK
authors.lastname: Singh
authors.forename: Shanmugam
authors.initials: S
authors.lastname: Manoharan
authors.forename: Krishnamurthy
authors.initials: K
authors.lastname: Vasudevan
authors.forename: Duraisamy
authors.initials: D
authors.lastname: Rajasekaran
authors.forename: Asokan
authors.initials: A
authors.lastname: Manimaran
authors.forename: Kathiresan
authors.initials: K
authors.lastname: Suresh
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene / Q000633:toxicity*; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002273:Carcinogens / Q000633:toxicity; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D006224:Cricetinae; D019938:Cyclin D1 / Q000235:genetics / Q000378:metabolism; D004224:Diterpenes / Q000627:therapeutic use*; D007124:Immunoenzyme Techniques; D008297:Male; D008647:Mesocricetus; D009061:Mouth Mucosa / Q000187:drug effects / Q000378:metabolism; D009062:Mouth Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D018809:Proliferating Cell Nuclear Antigen / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D016588:Anticarcinogenic Agents; D002273:Carcinogens; D004224:Diterpenes; D018809:Proliferating Cell Nuclear Antigen; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A; D019938:Cyclin D1; C030419:andrographolide; D015127:9,10-Dimethyl-1,2-benzanthracene